NASDAQ:BNTC - BENITEC BIOPHAR/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.00 +0.02 (+1.01 %)
(As of 03/22/2019 04:09 AM ET)
Previous Close$1.98
Today's Range$2.00 - $2.01
52-Week Range$1.01 - $4.90
Volume7,550 shs
Average Volume8,318 shs
Market Capitalization$22.06 million
P/E RatioN/A
Dividend YieldN/A
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology related to head and neck squamous cell carcinoma. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BNTC



Sales & Book Value

Annual Sales$3.65 million
Book Value$1.32 per share


Net Income$-9,020,000.00
Net Margins-247.57%


Market Cap$22.06 million
Next Earnings DateN/A
OptionableNot Optionable

BENITEC BIOPHAR/S (NASDAQ:BNTC) Frequently Asked Questions

What is BENITEC BIOPHAR/S's stock symbol?

BENITEC BIOPHAR/S trades on the NASDAQ under the ticker symbol "BNTC."

How often does BENITEC BIOPHAR/S pay dividends? What is the dividend yield for BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S declared a ... dividend on Monday, May 28th. Stockholders of record on Monday, June 4th will be given a dividend of $0.0029 per share on Friday, June 8th. The ex-dividend date is Friday, June 1st. View BENITEC BIOPHAR/S's Dividend History.

Has BENITEC BIOPHAR/S been receiving favorable news coverage?

News stories about BNTC stock have trended somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BENITEC BIOPHAR/S earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the near future.

Who are some of BENITEC BIOPHAR/S's key competitors?

What other stocks do shareholders of BENITEC BIOPHAR/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BENITEC BIOPHAR/S investors own include Amarin (AMRN), BIOLINERX LTD/S (BLRX), Neurocrine Biosciences (NBIX), Arena Pharmaceuticals (ARNA), Nightstar Therapeutics (NITE), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), Neovasc (NVCN), Gilead Sciences (GILD) and Allergan (AGN).

Who are BENITEC BIOPHAR/S's key executives?

BENITEC BIOPHAR/S's management team includes the folowing people:
  • Dr. Jerel A. Banks, CEO & Exec. Chairman
  • Ms. Georgina Kilfoil, Chief Devel. Officer (Age 50)
  • Ms. Megan Joan Boston, Exec. Director & Head of Operations - Australia
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Dr. Michael Graham, Head of Discovery & Founding Scientist


(BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

How do I buy shares of BENITEC BIOPHAR/S?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BENITEC BIOPHAR/S's stock price today?

One share of BNTC stock can currently be purchased for approximately $2.00.

How big of a company is BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S has a market capitalization of $22.06 million and generates $3.65 million in revenue each year.

What is BENITEC BIOPHAR/S's official website?

The official website for BENITEC BIOPHAR/S is

How can I contact BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S's mailing address is 99 Mount Street Suite 1201, Sydney C3, 2060. The biotechnology company can be reached via phone at 61-2-9555-6986 or via email at [email protected]

MarketBeat Community Rating for BENITEC BIOPHAR/S (NASDAQ BNTC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about BENITEC BIOPHAR/S and other stocks. Vote "Outperform" if you believe BNTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel